(Shared Conference with World Preclinical Congress and IO Pharma Congress)

Cambridge Healthtech Institute’s 2nd Annual

Patient-Derived Tumor Organoids

Developing, Validating, and Scaling Tumoroids for Screening

June 19-20, 2019


Multicellular cancer “oids” (tumoroids, spheroids, organoids) provide models of intermediate complexity between standard two-dimensional culture systems and tumors in vivo. “Oids” exhibit physiologically relevant cell-cell and cell-matrix interactions, gene expression and signaling pathway profiles, heterogeneity and structural complexity that reflect in vivo tumors. When cultured properly, tumoroids form with relative ease and demonstrate the effectiveness, reproducibility, and robustness of this in vitro model system. Join preclinical researchers at Cambridge Healthtech Institute’s 2nd Annual Patient-Derived Tumor Organoids conference as they share case studies on fundamental tumor biology, host-tumor interactions, and the use of higher-throughput screening platforms for anti-cancer drug discovery and development

GENERATING TRUE AVATARS OF THE PATIENT

KEYNOTE PRESENTATION: Implementation of Multi-Dimensional Cellular Tumor Models with Increased Translational Relevance in Preclinical Oncology Drug Development

Jason Ekert, PhD, MBA, Head, Complex In Vitro Models, R&D Platform Technology & Science, GlaxoSmithKline

Pathomimetic Cancer Avatars as Preclinical Models for High-Content Analysis

Bonnie F. Sloane, PhD, Distinguished Professor of Pharmacology, Wayne State University School of Medicine

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Hervé Tiriac, PhD, Associate Project Scientist, Department of Surgery, UC San Diego

MICROFLUIDIC TECHNOLOGIES TO SCREEN FOR PATIENT SPECIFIC IMMUNOTHERAPIES

Ex Vivo Profiling of Response to PD-1 Blockade Using Organotypic Tumor Spheroids

Elena Ivanova, PhD, Senior Scientist, Medical Oncology, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute

Cancer Models: Immune Checkpoint Blockade Therapies and Metastatic Disease

Roger D. Kamm, PhD, Green Distinguished Professor of Mechanical and Biological Engineering, Departments of Mechanical Engineering and Biological Engineering, Massachusetts Institute of Technology

TANK-Binding Kinase 1 (TBK1) as a Cancer Immunotherapy Target

Russell W. Jenkins, MD, PhD, Assistant Professor, Department of Medicine, Center for Cancer Research, Massachusetts General Hospital

HTS FOR ONCOLOGY

A PDX/Organoid Biobank of Advanced Prostate Cancer for Disease Modeling and Therapeutic Screening

Kathleen Kelly, PhD, Lab Chief, Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute

High Throughput Screening for Spheroids 

Louis Scampavia, PhD, Senior Scientific Director, Molecular Medicine Department, Scripps Research, Florida Campus

RECAPITULATING THE in vivo TUMOR MICROENVIRONMENT

Human Patient-Derived Tumor Organoids: Ex vivo Chemosensitivy Screening and Immune-Enhancing for Immunotherapy Responsiveness Screening

Aleksander Skardal, PhD, Assistant Professor, Wake Forest Institute for Regenerative Medicine


For more details on the conference, please contact:
Mana Chandhok
Conference Producer
Phone: 781-972-1350
Cambridge Healthtech Institute
Email: mchandhok@healthtech.com

For partnering and sponsorship information, please contact:


Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com